Abzena plc (ABZA LN)

Abzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally. The company?s services and technologies address critical research and development issues to enable the development of better biopharmaceutical products. It offers iTope, TCED, and EpiScreen technologies for the assessment of the potential immunogenicity of a biopharmaceutical product; and ThioBridge technology to produce more stable and homogeneous antibody drug conjugates. The company also provides Composite Human Antibodies and Composite Proteins for the immunogenic therapeutic antibodies and proteins; TheraPEG, HiPEG, CyPEG, and PolyPEG for the optimization of the pharmacokinetics and pharmacodynamics of protein therapeutics; and Composite CHO for the development of cell lines for the manufacture of therapeutic antibodies. It serves biopharmaceutical research and development industry. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.